JP2002511754A5 - - Google Patents

Download PDF

Info

Publication number
JP2002511754A5
JP2002511754A5 JP1999503953A JP50395399A JP2002511754A5 JP 2002511754 A5 JP2002511754 A5 JP 2002511754A5 JP 1999503953 A JP1999503953 A JP 1999503953A JP 50395399 A JP50395399 A JP 50395399A JP 2002511754 A5 JP2002511754 A5 JP 2002511754A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1999503953A
Other languages
English (en)
Japanese (ja)
Other versions
JP4272263B2 (ja
JP2002511754A (ja
Filing date
Publication date
Priority claimed from GBGB9712370.7A external-priority patent/GB9712370D0/en
Application filed filed Critical
Publication of JP2002511754A publication Critical patent/JP2002511754A/ja
Publication of JP2002511754A5 publication Critical patent/JP2002511754A5/ja
Application granted granted Critical
Publication of JP4272263B2 publication Critical patent/JP4272263B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50395399A 1997-06-14 1998-06-15 治療システム Expired - Fee Related JP4272263B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712370.7A GB9712370D0 (en) 1997-06-14 1997-06-14 Therapeutic systems
GB9712370.7 1997-06-14
PCT/GB1998/001731 WO1998057662A2 (en) 1997-06-14 1998-06-15 Therapeutic systems

Publications (3)

Publication Number Publication Date
JP2002511754A JP2002511754A (ja) 2002-04-16
JP2002511754A5 true JP2002511754A5 (enExample) 2005-09-08
JP4272263B2 JP4272263B2 (ja) 2009-06-03

Family

ID=10814135

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50395399A Expired - Fee Related JP4272263B2 (ja) 1997-06-14 1998-06-15 治療システム

Country Status (12)

Country Link
US (3) US6867231B1 (enExample)
EP (2) EP1468698A3 (enExample)
JP (1) JP4272263B2 (enExample)
AT (1) ATE311905T1 (enExample)
CA (1) CA2292608A1 (enExample)
CY (1) CY1105424T1 (enExample)
DE (1) DE69832702T2 (enExample)
DK (1) DK0988059T3 (enExample)
ES (1) ES2257810T3 (enExample)
GB (2) GB9712370D0 (enExample)
HK (1) HK1041824B (enExample)
WO (1) WO1998057662A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
GB9903019D0 (en) * 1999-02-10 1999-03-31 Microbiological Res Authority Nitroreductase enzymes
EP1210358A4 (en) * 1999-08-13 2005-01-05 Univ Brandeis PROOF OF NUCLEIC ACIDS
CN1315529A (zh) * 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人醌蛋白还原酶9和编码这种多肽的多核苷酸
WO2003025128A2 (en) * 2001-09-14 2003-03-27 Duke University Quinone reductase 2 and aldehyde dehydrogenase as therapeutic targets
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
EP1723227A4 (en) * 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
US8114626B2 (en) * 2004-02-10 2012-02-14 Trustees Of Dartmouth College Yeast strain and method for using the same to produce nicotinamide riboside
US7910593B2 (en) 2004-04-09 2011-03-22 Chugai Seiyaku Kabushiki Kaisha Water-soluble prodrugs
EP2805719A1 (en) * 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
GB0517957D0 (en) 2005-09-03 2005-10-12 Morvus Technology Ltd Method of combating infection
GB0526552D0 (en) 2005-12-29 2006-02-08 Morvus Technology Ltd New use
GB2442202A (en) 2006-09-30 2008-04-02 Morvus Technology Ltd Vermin poison
CA2956163C (en) 2014-07-24 2023-01-10 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
ES2963057T3 (es) 2015-03-09 2024-03-25 Grace W R & Co Forma cristalina de ribósido de nicotinamida
NZ735411A (en) * 2015-03-16 2021-07-30 Chromadex Inc Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
WO2017011788A1 (en) * 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
NZ803738A (en) 2016-11-11 2024-05-31 Chromadex Inc Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
EP3554285A4 (en) 2016-11-29 2021-01-20 University of Iowa Research Foundation USE OF NAD PRECURSORS TO IMPROVE THE HEALTH OF MOTHER AND / OR OFFspring
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US440859A (en) * 1890-11-18 Wire-rope machine
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
JPS5460386A (en) * 1977-10-20 1979-05-15 Fuji Photo Film Co Ltd Photopolymerizable composition
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
YU44186B (en) 1978-12-22 1990-04-30 Biogen Nv Process for obtaining recombinant dnk molecules
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPS60184252A (ja) * 1984-03-02 1985-09-19 Canon Inc 電子写真感光体
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
NZ225599A (en) 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
ATE135045T1 (de) 1988-07-23 1996-03-15 Delta Biotechnology Ltd Sekretorische leader-sequenzen
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
GB8929097D0 (en) 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9001641D0 (en) 1990-01-24 1990-03-21 Imp Cancer Res Tech Compounds
JP4115514B2 (ja) 1991-10-23 2008-07-09 キャンサー・リサーチ・キヤンペーン・テクノロジー・リミテツド Ｃｂ １９５４およびその類似体を細胞障害性の形態に還元するための細菌のニトロリダクターゼ
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
GB9200415D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
GB9323008D0 (en) * 1993-11-05 1994-01-05 Connors Thomas Improvements relating to cancer therapy
GB9516943D0 (en) * 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
GB9524942D0 (en) 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
EP0869818A1 (en) 1995-12-29 1998-10-14 AEPACT Limited Cytotoxic agents
WO1998022577A1 (en) 1996-11-15 1998-05-28 Maria Grazia Masucci Fusion proteins having increased half-lives
GB9624993D0 (en) 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems

Similar Documents

Publication Publication Date Title
JP2000510751A5 (enExample)
JP2000509637A5 (enExample)
JP2000509942A5 (enExample)
JP2000509912A5 (enExample)
JP2001511668A5 (enExample)
JP2000509635A5 (enExample)
JP2000507042A5 (enExample)
JP2002503166A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2001506183A5 (enExample)
JP2000508680A5 (enExample)
JP2002504172A5 (enExample)
JP2001512519A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)